Omnicell, Inc.

Omnicell, Inc.

OMCL
Omnicell, Inc.US flagNASDAQ
40.86
USD
-0.97
- -
1.86BMarket Cap
Omnicell, Inc.
OMCL
(NASDAQ)

Recent

price

40.86

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.81
7.41
9.43
10.96
12.37
13.51
19.25
19.01
20.06
21.63
20.95
26.04
29.19
25.37
24.15
25.78
26.83
Revenue per Share
0.15
0.31
0.49
0.69
0.86
0.86
0.27
0.81
0.96
1.48
0.76
1.79
0.13
-0.45
0.27
0.04
0.45
Basic EPS, GAAP
0.35
0.55
0.57
1
1.19
0.51
0.57
-0.15
1.26
2.01
3.08
3.99
0.38
2.79
2.93
1.51
2.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.37
-0.05
0.44
1.11
1.94
2.78
2.78
4.26
5.03
6.24
6.83
8.48
8.8
8.19
8.32
8.38
8.68
Book Value per Share
7.11
7.31
2.9
4.03
4.63
3.87
-3.31
0.26
3.65
7.21
4.84
0.76
1.63
3.88
5.69
5.86
6.59
Tangible Book Value per Share
33
33
33
35
36
36
36
37
39
41
43
43
44
45
46
46
46
Basic Weighted Avg Shares
222
246
314
381
441
485
696
713
787
897
892
1,132
1,296
1,147
1,112
1,185
1,225
Sales/Revenue/Turnover
4.8
6.61
8.64
9.27
11.25
9.33
3.08
1.56
5.64
8.73
3.98
7.91
-0.18
-3.04
0.03
0.44
2.75
Operating Margin (%)
9
8
13
18
20
26
58
52
51
64
72
85
99
96
90
87
85
Depreciation Expense
5
10
16
24
31
31
10
31
38
61
32
78
6
-20
13
2
20
Net Income, GAAP
50.87
35.43
40.25
31.55
37.08
33.48
24.82
- -
- -
17.04
- -
- -
- -
- -
51.04
81.88
45.89
Effective Tax Rate (%)
2.2
4.23
5.15
6.3
6.92
6.35
1.4
4.28
4.79
6.84
3.61
6.88
0.44
-1.78
1.13
0.17
1.67
Profit Margin (%)
206
223
98
141
171
139
134
147
193
246
553
-95
453
560
220
203
239
Working Capital
- -
- -
- -
- -
- -
- -
246
195
135
101
516
40
606
604
198
192
191
LT Debt
265
283
308
349
390
402
432
554
680
845
968
1,147
1,130
1,189
1,243
1,232
1,257
Total Equity
2.07
3.82
5.49
7.35
8.42
7.56
2.96
- -
- -
7.33
- -
- -
- -
- -
0.01
0.06
1.17
Return on Invested Capital (%)
-33.89
-153.39
249.72
90.58
56.71
36.42
4.29
- -
- -
17.46
- -
- -
- -
- -
1.43
0.3
3
Return on Capital (%)
- -
- -
- -
90.26
56.71
36.42
9.74
23.46
21.12
26.88
11.72
23.61
1.49
-5.35
3.33
0.53
5.29
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
12
12
12
LT Borrowings
167
168
168
LT Finance Leases
28
25
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
1,410
2,082
1,524

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
660
680
722
Cash, Cash Equivalents & STI
193
211
254
Accounts Receivable, Net
246
217
250
Inventories
107
101
99
Total Current Liabilities
457
477
483
Payables & Accruals
148
124
139
ST Debt
12
12
12
Deferred Revenue
247
283
286

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.31%
5.19%
-0.92%
Free Cash Flow
-41.8%
108.1%
-48.59%
Net Income, GAAP
-47.35%
-131.35%
-83.62%
Sales/Revenue/Turnover
10.33%
6.67%
6.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
246
277
282
307
1,112
2025
270
291
311
314
1,185
2026
310
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.34
0.08
0.19
0.34
0.27
2025
-0.15
0.12
0.12
-0.05
0.04
2026
0.25
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Omnicell, Inc. is a healthcare technology company specializing in medication management solutions and adherence tools designed to enhance healthcare delivery and operational efficiency. The company offers an extensive portfolio that includes automated medication dispensing systems; pharmacy automation equipment; medication adherence packaging; analytics and inventory management software; point-of-care pharmacy automation; adherence packaging systems under the MyMD packaging brand; and clinical decision support applications. Omnicell serves healthcare providers, pharmacies, hospitals, and long-term care facilities across the United States, Canada, and select international markets. Founded in 1992, the company is headquartered in Mountain View, California. In the past 1-2 years, Omnicell has focused on expanding its clinical and financial analytics capabilities, integrating new software enhancements to improve medication safety and operational workflows. The company has also been active in strategic partnerships that broaden its technology ecosystem and has launched updated versions of its adherence packaging solutions. Omnicell continues to extend its presence in the pharmacy automation market through selective acquisitions and innovation in medication management systems. These initiatives reflect a strategic shift toward comprehensive service offerings that combine hardware, software, and analytics to support a data-driven approach in healthcare operations. Omnicell operates primarily in the healthcare technology and medical devices industry, targeting hospital systems, health systems, retail pharmacies, and senior care providers. Its product and service offerings are designed to address challenges in medication adherence, reduce medication errors, optimize pharmacy workflows, and improve patient outcomes. The company maintains a broad geographic footprint across North America with growing influence internationally, supported by its network of subsidiaries and partners specializing in healthcare technology solutions.

Company News

APIChatGPT
  • Omnicell to Report Q2 Earnings: OmniSphere in Focus

  • Should You Continue to Hold OMCL Stock in Your Portfolio Now?

  • What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?

  • Nnamdi Njoku Appointed President of Omnicell

  • Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

  • OMCL or HIMS: Which Is the Better Value Stock Right Now?

  • Do Options Traders Know Something About Omnicell Stock We Don't?

  • OMCL vs. HIMS: Which Stock Is the Better Value Option?

  • Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

  • Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

  • Omnicell: Why I'm Long Into Q2 Earnings Despite The Bookings Wobble

  • Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

  • Top Robotics Stocks Worth Investing in the Second Half of 2026

  • Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know

  • Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?

  • A Look at Omnicell Inc (OMCL) After 4.1% Gain -- GF Value $38.65 vs Price $43.62

  • Is Omnicell Stock a Smart Addition to Your Portfolio Now?

  • Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

  • Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

  • Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?